Diálisis de albúmina de paso único (SPAD) como soporte hepático extracorpóreo en paciente COVID-19 crítico: caso clínico
Author
dc.contributor.author
Ramírez Guerrero, Gonzalo
Author
dc.contributor.author
Zurita Poza, Anita Valeria Paulina
Author
dc.contributor.author
Baghetti Hernández, Romyna Victoria
Author
dc.contributor.author
Villagrán Cortés, Francisco Joaquín
Author
dc.contributor.author
Segovia Hernández, Bárbara Andrea
Author
dc.contributor.author
Aguirre Adones, Lisette Alejandra
Author
dc.contributor.author
Garay, Osvaldo
Admission date
dc.date.accessioned
2024-07-11T20:46:12Z
Available date
dc.date.available
2024-07-11T20:46:12Z
Publication date
dc.date.issued
2022
Cita de ítem
dc.identifier.citation
Rev Med Chile 2022; 150: 1540-1544
es_ES
Identifier
dc.identifier.issn
0034-9887
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/199548
Abstract
dc.description.abstract
Liver transplantation is the only effective therapy to reduce the high mortality
associated with acute liver failure and acute on chronic liver failure (ACLF).
Single-pass albumin dialysis (SPAD) is an extracorporeal supportive therapy
used as a bridge to liver transplantation or regeneration. We report a 44-year-old
man with alcoholic cirrhosis admitted for critical COVID-19 pneumonia that
evolves with ACLF. SPAD technique was performed completing six sessions, with
a reduction of bilirubin and ammonia levels. He evolved with severe respiratory
failure and refractory septic shock, dying. SPAD is a safe and efficient technique
aimed to eliminate liver toxins, preventing multiorgan damage interrupting
the process known as the “autointoxication hypothesis”. It is easy to implement
in any critical patient unit and has lower costs than other extracorporeal liver
support therapies.
es_ES
Lenguage
dc.language.iso
es
es_ES
Publisher
dc.publisher
Sociedad Médica de Santiago
es_ES
Type of license
dc.rights
Attribution-NonCommercial-NoDerivs 3.0 United States